Omics-guided therapy is changing how advanced prostate cancer is classified and treated
Prostate cancer remains one of the most consequential malignancies in men worldwide, with roughly 1.5 million new diagnoses and 400,000 deaths each year. The projected near-doubling of both burdens by 2040 gives this disease a particularly urgent clinical profile. Once the illness advances to metastatic castration-resistant prostate cancer, median overall survival falls to about 24 months, and treatment benefit erodes with each additional line of therapy. In that setting, the case for more precise biologic selection becomes difficult to ignore.
Omics platforms have moved from aspirational research tools to practical instruments for clinical decision-making. Genomics, transcriptomics, proteomics, and related molecular methods generate high-resolution data that can reveal how a tumor grows, adapts, and resists treatment. Among these approaches, genomic profiling has become especially influential in advanced prostate cancer, where DNA damage response alterations can help direct therapy using tissue samples or circulating tumor DNA. The central premise is straightforward: if the tumor’s molecular wiring is identifiable, treatment can be matched more intelligently to the biology driving progression.
DNA damage response alterations now sit at the center of precision selection
The most established omics application in advanced prostate cancer involves DDR gene alterations. These changes can identify tumors with vulnerabilities in DNA repair machinery, creating a therapeutic opening for agents that exploit impaired repair pathways. Tissue testing and circulating tumor DNA both contribute to this process, allowing clinicians to detect relevant genomic features even when archival tissue is limited or inaccessible. In practice, this expands the number of patients who can be molecularly profiled, which matters in a disease that often becomes metastatic and treatment-refractory before repeated tissue sampling is realistic.
This review places DDR-directed selection in the context of therapies that already have survival benefit. Rather than treating omics as a theoretical add-on, the article frames it as a tool for predicting which patients are most likely to benefit from approved agents. It also addresses how molecular profiling may steer enrollment into clinical trials, where biomarker-selected populations can sharpen drug development and reduce the noise created by biologically heterogeneous cohorts. In advanced prostate cancer, where response can vary sharply from one patient to the next, this level of stratification has immediate clinical relevance.
A tumor with repair defects is not simply a different molecular label; it may be a different disease process with different drug sensitivities.
From biomarker discovery to trial allocation and drug repurposing
The review organizes the field along three converging trajectories. First, omics can predict response to approved agents with proven survival benefit. Second, it can stratify patients for experimental therapies in clinical trials. Third, it can inform drug development, including repurposing strategies that leverage existing compounds in molecularly defined subgroups. These three directions are not separate silos. They represent a continuum from bedside testing to translational pipeline to therapeutic innovation.
Drug repurposing deserves particular attention in a disease where therapeutic options narrow after repeated progression. Omics can expose pathway dependencies that are not obvious from histology or prostate-specific antigen trends alone. A molecular signature may suggest sensitivity to a drug class already available for another indication, shortening the route from biologic insight to clinical use. In that way, molecular profiling does more than identify prognosis; it can redirect the therapeutic map.
The article also makes clear that advanced omics has practical value because it reduces reliance on broad clinical assumptions. Two patients with the same stage of disease may carry very different molecular drivers, and those differences shape therapeutic response. As omics methods mature, they allow treatment selection to move closer to the actual biology of the cancer rather than to a one-size-fits-all model built mainly on stage and prior exposure.
Circulating tumor DNA expands access to molecular information in advanced disease
Circulating tumor DNA has particular appeal in metastatic castration-resistant disease because it offers a less invasive route to genomic information. When tissue is limited, degraded, or unrepresentative of the current disease state, blood-based profiling can capture actionable alterations. This matters because advanced prostate cancer evolves under intense selective pressure from hormonal therapy and subsequent lines of treatment. The molecular profile seen at diagnosis may no longer reflect the biology at progression.
By allowing repeated sampling, circulating tumor DNA can also support longitudinal monitoring. That creates the possibility of tracking resistance as it emerges, rather than waiting for overt clinical failure. In a disease where efficacy drops after each treatment line, the ability to reassess molecular status may improve the timing of therapeutic switches and trial referral. The biological logic is compelling: as resistant clones dominate, an updated molecular readout may be the only way to keep treatment aligned with the current tumor population.
The main barrier is not technology alone, but translation into routine care
The omics toolbox is now sufficiently advanced to generate clinically meaningful data, but its utility depends on interpretation, access, and integration into treatment pathways. High-dimensional datasets can identify mechanisms underlying prostate cancer pathology, yet the presence of molecular information does not automatically translate into a better outcome. Molecular findings must be linked to therapies that are available, validated, and usable in real-world oncology practice. Without that bridge, precision oncology risks becoming descriptive rather than therapeutic.
This review is deliberately framed around recent research and clinical trial reports from the last five years, reflecting how quickly the field has matured. That time window includes growing use of genomic profiling, broader interest in biomarker-driven trial designs, and more explicit attention to drug repurposing frameworks. The unifying message is not that omics replaces established prostate cancer care, but that it can refine it in ways that matter most when disease is advanced and survival is limited.
For now, the clearest clinical value lies in identifying DDR alterations, guiding selection for approved and investigational therapies, and using molecular data to match patients with the right treatment at the right moment. What remains unresolved is how widely these approaches can be implemented across health systems and how consistently they will improve outcomes outside specialized centers. The field has moved beyond proof of concept; the next challenge is making molecular precision routine rather than exceptional.